Read More: eGenesis Raises $191 Million Series D Financing to Advance Lead Program for Kidney Transplant
According to the most recent estimates, more than 100,000 people in the U.S. need a transplant due to a failing organ.
The waitlist is growing. More than 36,000 patients were added to the kidney transplant waitlist alone in 2020 in the U.S.
On average, only 106 organ transplants of any kind take place each day in the U.S. The gap between need and availability is always growing.
The supply of human donor organs and cells cannot serve all patients in need. Every day, 20 people die waiting in the U.S. and this devastating shortage is growing worse.
While these numbers are striking, they don’t tell the whole story of the transplant shortage crisis. That story includes the experiences of individuals and families from all backgrounds — their fear, their suffering, and their hope.
At eGenesis, we ask, “Why can’t we end this crisis?” We envision a world in which the supply of transplantable organs and cells does not determine the length or quality of one’s life.
Through our transformative research, we are developing HuCo™ organs and cells to meet the increasing need. Our eGenesis Genome Engineering and Production (EGEN™) Platform leverages advances in gene editing technologies to address the historical challenges of xenotransplantation. Our goal is to improve the lives of patients in need of a transplant, their families, and those who care for them.
We are excited to share this powerful and promising story with you.